Mangaluru: Two officials get 1 year jail for accepting Rs 3,000 bribe

The United States of America has bought almost the entire world's supply of remdesivir, one of just two drugs proven to treat COVID-19. 

“President Trump has struck an amazing deal to ensure Americans have access to the first authorised therapeutic for Covid-19,” said the US health and human services secretary, Alex Azar. 

“To the extent possible, we want to ensure that any American patient who needs remdesivir can get it. The Trump administration is doing everything in our power to learn more about life-saving therapeutics for Covid-19 and secure access to these options for the American people.”

The announcement implies that no other country in the world will be able to buy remdesivir for next three months at least.

The anti-viral drug patented by the US-based Gilead biotech firm is the only one approved by the European Medicines Agency (EMA) to treat patients with the novel coronavirus.

The Trump administration has already shown that it is prepared to outbid and outmanoeuvre all other countries to secure the medical supplies it needs for the US.

“They’ve got access to most of the drug supply [of remdesivir], so there’s nothing for Europe,” said Dr Andrew Hill, senior visiting research fellow at Liverpool University.

Remdesivir, the first drug approved by licensing authorities in the US to treat Covid-19, is made by Gilead and has been shown to help people recover faster from the disease. 

The first 140,000 doses, supplied to drug trials around the world, have been used up. The Trump administration has now bought more than 500,000 doses, which is all of Gilead’s production for July and 90% of August and September.

Mangaluru, May 27: The Dakshina Kannada PU College Principals' Association on Wednesday appealed to the authorities to postpone the evaluation of PUC II answer scripts, as the Novel Coronavirus was still active and there was all possibility of the infection spreading.

Speaking to reporters here, Association President Umesh Karkera said, ''It is our duty to evaluate the answer scripts. But amid the fear of COVID-19 and lockdown, evaluators are not able to reach the valuation Centre to take up the work.

''The department of pre-university education has asked the Deputy Chief Examiners and the Assistant Examiners to reach the venue on May 27 and 29, respectively, to take up the evaluation work.